Pancreatic Cancer Research

GrantR43National Cancer Institute

ERASE - A new dual thermal ablation/SCN device system for treating pancreatic cancer

Activity
R43
Institute
National Cancer Institute
Fiscal years counted
2016
Amount counted
$295,410

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Abstract public domain (NIH RePORTER)

CPSI Biotech is a medical device company that specializes in thermal ablation systems for treating a variety of cancers. The SCN systems developed by CPSI are now in prototype form and have been animal tested at a variety of venues including Johns Hopkins School of Medicine. CPSI also specializes in novel probes and catheters designed for the cryoablation of cancers for use with the SCN system. This Phase 1 SBIR application proposes to develop a new device and treatment regime for treating pancreatic cancer (PaCa). CPSI has named this new approach ERASE (Endoscopic-based combinatoRial Ablative and Sensitization therapeutic procedurE). The project includes the development of a (1) next gen dual thermal ablation (DTA) catheter with an integrated intertumoral drug delivery channel (QuadProbe) and requisite re-engineering of the SCN system as well as (2) identifying thermal sensitizers that will make DTA more effective. Under Phase 1 studies the investigational team will identify and test the effectiveness of the targeted chemical molecular sensitizers in conjunction with the SCN and QuadProbe catheter to develop ERASE to more effectively treat resectable and nonresectable PaCa. Further, through the incorporation of select site directed drug therapy the combinatorial ERASE protocol will help address the challenges with the management of metastatic disease targeting undetected satellite cancer populations. The intent of this project is to develop and characterize a next generation, flexible, closed loop, needle catheter-based endoscopic device (QuadProbe) for the treatment of PaCa employing a minimally invasive outpatient procedure. The prototype device and preliminary data collected to date strongly support the potential of this approach. The major goals of this Phase 1 proposal are to (1) develop the QuadProbe DTA catheter, (2) identify a series of drugs that when used with DTA increase the destruction of PaCa cells, (3) develop the combinatorial drug/ablation ERASE protocol, (4) optimize ERASE in an ex vivo tissue model, and (5) conduct a pilot in vivo study for validation and technology/procedural development. Phase 2 studies will be dedicated to optimizing the four-way function of the QuadProbe (freezing, heat, thermal sentizer ejection, biopsy/tissue aspirate collection) as well as working with our Johns Hopkins colleagues analyzing and modulating the immune response triggered in patients who have undergone the ERASE protocol so that patient outcome can be improved. The successful completion of this project will lead to new technology and therapy for the management of PaCa as well as provide data in support of establishing the thermal dose parameters necessary for optimal clinical application of the proposed, as well as other, ablation devices for the treatment of PaCa. This project will leverage and combine the expertise of researchers from CPSI, Binghamton University, and Johns Hopkins School of Medicine to develop a new surgical/sensitizer approach to more effectively treat PaCa. Once completed, this project will provide for an effective, minimally invasive treatment option for individuals suffering from PaCa contributing to efforts for improving patient survival and quality of life.

Public health relevance public domain (NIH RePORTER)

CPSI Biotech is a medical device company that has developed a surgical instrument that freezes cancer tissue so that it is destroyed. This grant application proposes to test the concept that both heat and freezing are more effective at ablating (killing) pancreatic cancer - one of the most lethal cancers. CPSI hypothesizes that the application of agents called "thermal sensitizers" will make the dual thermal ablation device more effective by killing more pancreatic cancer cells. The key invention will be CPSI's QuadProbe - the first probe that can freeze, heat, freeze/heat, eject thermal sensitizers and remove biopsy/debris from the pancreatic cancer site. CPSI's partners are from Johns Hopkins School of Medicine and they will do the necessary animal/human studies. Finally, both CPSI and Johns Hopkins hypothesize that this new dual thermal ablation technology may trigger an immune response in patients that can be leveraged so that the metastatic nature of the disease can be more effectively treated resulting in better patient outcome.